NCT01783951

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy in Patients With Advanced Gastric Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
BIOLOGICAL	DC-CIK	Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
DRUG	S-1	The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
DRUG	Cisplatin	Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.

Timeline

• Start date: 2013-02-01
• Primary completion: 2018-02-01
• Completion: 2018-06-01
• First posted: 2013-02-05
• Last updated: 2018-07-19

Locations

1 site across 1 country: China